Risdiplam is the sole orally administered drug accredited for the therapy of SMA. It had been FDA permitted in 2020 to be used in patients two months of age and older, and it features being an SMN2 gene splicing modifier bringing about increased amounts of SMN protein. Oral administration is https://sethmdufq.life3dblog.com/26326654/the-su5408-diaries